Our breast pathology program provides personalized and accessible pathology services to help you deliver definitive diagnoses, ensure prompt treatment decisions and provide superior patient care.
Experienced, fellowship-trained, breast pathologists and cytopathologists review
more than 28,000 breast FNAs, biopsies and excisions every year
Prompt specimen turnaround for second opinions requested at other institutions
Remote consultation and tumor board attendance via telepathology are available upon request
Specimen radiograph control for all cases in which calcifications need to be histologically identified
State-of-the-art reporting with callback discussion for all malignant cases
Daily intradepartmental case reviews via consensus conference include pre-malignant and malignant cases, significant laboratory test results (e.g., HER2) and other cases of concern
Comprehensive Test Menu:
- Adherence to ASCO/CAP guidelines for processing and reporting
- Continuous updates to our programs based on breakthroughs in clinical testing and research
- Multi-platform testing for prognostic markers (ER, PR, HER2 and Ki-67) and evaluation by cell-image analysis
- Individualized metastasis risk assessment and molecular subtyping for patients with breast cancer provided with MammaPrint® and BluePrint®
Clear Reports
Our clear easy-to-read reports deliver definitive diagnoses for better treatment decisions
Comprehensive HER2 Testing
- Dual probe HER2 FISH gene amplification assay to predict Herceptin®, PERJETA® and KADCYLA® benefit
- Bright-field capable HER2 Dual ISH DNA probe cocktail assay to complement HER2 FISH
